News
IPHYF
2.250
NaN%
--
Innate Pharma Reports Voting Outcomes from 2026 Annual General Meeting
TipRanks · 05/22 10:30
Innate Pharma to Court Investors at Jefferies Global Healthcare Conference 2026
TipRanks · 05/19 10:33
H.C. Wainwright Sticks to Their Buy Rating for Innate Pharma (IPHA)
TipRanks · 05/14 10:36
Innate Pharma: Buy Rating Reaffirmed on Pipeline Momentum and De‑Risking Catalysts; $8 Price Target Unchanged
TipRanks · 05/14 10:16
Innate Pharma Posts Q1 2026 Results as Key Oncology Trials Advance and Cash Runway Tightens
TipRanks · 05/13 12:42
Innate Pharma Updates Share Capital and Voting Rights as of April 16, 2026
TipRanks · 05/12 10:30
Innate Pharma Schedules May 13 Webcast on First-Quarter 2026 Business Progress
TipRanks · 05/06 10:58
Innate Pharma Plans Investor Meetings at D. Boral Capital Global Conference in New York
TipRanks · 04/23 10:30
Innate Pharma Showcases Encouraging Phase 2 IPH5201 Lung Cancer Data at AACR 2026
TipRanks · 04/17 19:28
Innate Pharma Sets May 21, 2026 Date for Annual General Meeting in Marseille
TipRanks · 04/13 10:48
Innate Pharma Reports Share Capital and Voting Rights as of April 9, 2026
TipRanks · 04/13 10:48
Innate Pharma to Showcase Oncology Pipeline at AACR 2026 Partnering Event
TipRanks · 04/08 10:59
Innate Pharma: Underappreciated Topo‑I ADC Pipeline and Differentiated IPH4502 Support Buy Rating
TipRanks · 04/07 16:55
Innate Pharma Balances Pipeline Progress With Cash Strain
TipRanks · 04/04 00:07
Innate Pharma to Engage Investors at Kempen Life Sciences Conference in Amsterdam
TipRanks · 04/03 11:27
Innate Pharma Files 2025 Annual Reports with AMF and U.S. SEC
TipRanks · 04/02 10:32
Innate Pharma Posts 2025 Results, Flags H2 2026 CTCL Phase 3 Start Amid Cash Runway to Q3
TipRanks · 03/26 10:29
Innate Pharma GAAP EPS of -€0.55, revenue of €9.01M
Seeking Alpha · 03/26 07:53
Innate Pharma Sets March 26 Webcast to Present Full-Year 2025 Results
TipRanks · 03/19 11:47
Innate Pharma assumed with a Buy at BTIG
TipRanks · 03/11 20:28
More
Webull provides a variety of real-time IPHYF stock news. You can receive the latest news about Innate Pharma Marseille through multiple platforms. This information may help you make smarter investment decisions.
About IPHYF
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.